Key result
hANP infused with angiotensin II attenuates maximal aldosterone secretion ~25% without altering hemodynamics or renal excretion.
Why the study?
The effects of physiological and pharmacological doses of human atrial natriuretic peptide on angiotensin II-mediated hemodynamics, renal excretion, and aldosterone release in conscious dogs were not fully characterized.
p-value: p=<0.05
In conscious dogs, physiological doses of hANP attenuate ANG II-stimulated aldosterone secretion without affecting ANG II-mediated renal or hemodynamic responses, whereas pharmacological doses decrease blood pressure.
No takes yet. Share an insight, caveat, or question.
Physiological hANP may selectively blunt aldosterone secretion; leaves open translation to human cardiorenal physiology or therapy.
Kuhlen et al. (1992) studied Conscious, chronically instrumented dogs (n=5). hANP-(99-126) vs. Angiotensin II alone was evaluated on Hemodynamics, renal excretion, and aldosterone release (p=<0.05). Simultaneous infusion of physiological hANP with angiotensin II attenuated maximal aldosterone secretion (362 vs 481 pg/ml; P<0.05) but did not alter hemodynamic or renal excretion effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: